RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer

  • Authors:
    • Zhenhua Li
    • Xiaojing Chang
    • Dongqiu Dai
    • Peng Deng
    • Qiang Sun
  • View Affiliations

  • Published online on: February 20, 2014     https://doi.org/10.3892/or.2014.3039
  • Pages: 1661-1668
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To better understand the role of the N-Terminal Ras association domain family (RASSF) genes in the development of gastric cancer, we examined the expression of RASSF7 and RASSF10 and RASSF10 methylation in gastric cancer. We found that RASSF10 expression was lost in six gastric cancer cell lines, and was rescued by a DNA demethylating agent and a histone deacetylase inhibitor. However, RASSF7 expression was strong in four cancer cell lines as well as in 87% of primary gastric cancer tissues. In contrast, RASSF7 expression was moderate in the GES-1 cell line and negative in 33.3% of the corresponding non-cancerous tissues. Analysis of RASSF10 methylation by methylation-specific PCR (MSP) and sequencing revealed that the methylation frequency in primary gastric carcinoma tissues was significantly higher compared to that in adjacent non-carcinoma tissues (61.6 vs. 38.4%; p<0.01). The methylation frequency in the tumor with invasion depth at T3 and T4 was significantly higher compared to that with invasion depth at T1 and T2 (67.1 vs. 37.5%; p<0.05). Hypermethylation of RASSF10 was found in the patients with lymph node metastasis, compared to those with unaffected lymph nodes (68.8 vs. 40.9%; p<0.05). Among the 4 gross types of the Borrmann classification, i.e. EGC, Borrmann Ⅰ, Borrmann Ⅱ, Borrmann Ⅲ and Borrmann Ⅳ, the last one was more frequently methylated (85.7 vs. 56.9%; p<0.05). The present study revealed that RASSF10 is an epigenetically silenced gene involved in tumor invasion and metastasis in gastric cancer, suggesting that the methylation status of RASSF10 may be a useful indicator to predict the malignant degree of gastric cancer.
View Figures
View References

Related Articles

Journal Cover

2014-April
Volume 31 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Z, Chang X, Dai D, Deng P and Sun Q: RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer. Oncol Rep 31: 1661-1668, 2014.
APA
Li, Z., Chang, X., Dai, D., Deng, P., & Sun, Q. (2014). RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer. Oncology Reports, 31, 1661-1668. https://doi.org/10.3892/or.2014.3039
MLA
Li, Z., Chang, X., Dai, D., Deng, P., Sun, Q."RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer". Oncology Reports 31.4 (2014): 1661-1668.
Chicago
Li, Z., Chang, X., Dai, D., Deng, P., Sun, Q."RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer". Oncology Reports 31, no. 4 (2014): 1661-1668. https://doi.org/10.3892/or.2014.3039